UE 2024 - PEEU Commission PresidencyVon der Leyen: no mention of biotechnologyIn view of her confirmation as EU Commission President, biotech associations have reminded Ursula von der Leyen of her promise to strategically promote the sector with an EU Biotech Act 2025. more ➔
EllegaardImmunologyScientists prevent transplant rejectionScientists at Hannover Medical School (MHH) have genetically engineered pig lungs in such a way that immunosuppressants could be reduced during transplants. more ➔
Biocytogen Co LtdADCSOTIO partners with Biocytogen to expand A...Czech Sotio Biotech has inked an R&D and licence option agreement with Chinese antibody maker Biocytogen. more ➔
Draupnir Bio ApSProtein degradersDraupnir Bio ApS raises further equityTargeted protein degradation Draupnir Bio Aps has raised further €12m in an equitiy investment to advance its preclinical pipeline. more ➔
InvestmentCordenPharma invests €900m in peptide pa...CordenPharma is making a record investment of about €900m over the next three years in expanding its peptide platform, both at its Colorado, US site and in Europe. more ➔
CatalymFinancing roundCatalym raises US$150mGerman cancer specialist Catalym GmbH has raised US$150m to finance proof-of-concept studies. more ➔
Hearing lossSensorion achieves milestones in Phase II...French Sensorion SA has reported new efficacy endpoints data from SENS-401 in a Phase II study for the preservation of residual hearing loss. more ➔
Rentschler Biopharma SEProduction capacityRentschler doubles cGMP capacityIn the largest expansion in the company’s 150-year history, the Laupheim-headquartered CDMO Rentschler Biopharma SE has launched a new production line at its site in Milford, USA. more ➔
Series A financingSciRhom GmbH closes €63m Series A financ...German iRhom2-targeted antibody specialist SciRhom GmbH has closed an oversubscribed €63m Series A financing that will be used to provide clinical proof of concept in autoimmune disorders. more ➔
AcquisitionLigand Pharma to acquire Apeiron BiologicsAustrian Apeiron Biologics goes to Ligand Pharmaceuticals for US$100m. more ➔
UE 2024 - PE
Ellegaard
Biocytogen Co Ltd
Draupnir Bio ApS
Catalym
Rentschler Biopharma SE
